Sunesis expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company's expectations with
regard thereto or any change in events, conditions or circumstances on
which any such statements are based.
SUNESIS PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
December 31, December 31,
2007 2006
ASSETS (Note 1)
Current assets:
Cash and cash equivalents $11,726,126 $6,075,449
Marketable securities 35,957,933 57,029,199
Prepaids and other current
assets 945,583 1,082,817
Total current assets 48,629,642 64,187,465
Property and equipment, net 4,238,498 4,728,929
Deposits and other assets 377,798 359,974
Total assets $53,245,938 $69,276,368
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other
accrued liabilities $4,515,426 $3,439,422
Accrued compensation 2,225,868 2,323,742
Current portion of deferred
revenue 1,227,031 2,260,478
Current portion of equipment
financing 953,940 885,273
Total current liabilities 8,922,265 8,908,915
Non-current portion of deferred
revenue - 1,143,159
Non
'/>"/>
SOURCE Sunesis Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1.
Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer2.
Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration3.
Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development4.
Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results5.
Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics6.
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs7.
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 20088.
Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference9.
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint10.
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 200811.
Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting